The Biostatistics Resource Group (BRG) provides biostatistical collaboration, consultation, and quantitative research resources to clinical, laboratory, and prevention scientists engaged in the planning, conduct, analysis, quality assurance, and interpretation of research studies. Additionally, members of this shared resource collaborate with oncology researchers to develop biostatistical methods to improve the efficiency of therapeutic, diagnostic, prevention, and intervention studies, and to improve the treatment of patients enrolled in clinical trials. The services of the resource satisfy four primary objectives: (1) to provide statistical services in support of cancer research in laboratory experiments and clinical trials;(2) to play a direct role in the planning and review of clinical protocols;(3) to provide educational programs in biostatistical methods; and (4) to design, develop, and implement software and database systems to support various computational needs of cancer researchers. The BRG is composed of 17 faculty statisticians as well as 28 statistical analysts;7 of whom are Ph.D. level, and 21 of whom are Master's level. In the last 5 years, the BRG provided biostatistical support and consultation services to 495 investigators from 20 programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379455
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$891,643
Indirect Cost
$314,251
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Peng, Bo; Wang, Gao; Ma, Jun et al. (2018) SoS Notebook: an interactive multi-language data analysis environment. Bioinformatics 34:3768-3770
Ariza-Heredia, Ella J; Chemaly, Roy F; Shahani, Lokesh R et al. (2018) Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int 31:639-648
Kraft, Ira L; Akshintala, Srivandana; Zhu, Yuelin et al. (2018) Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clin Cancer Res 24:753-765
Rozovski, Uri; Harris, David M; Li, Ping et al. (2018) STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9:21268-21280
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Wang, Jian; Shete, Sanjay (2018) Estimation of indirect effect when the mediator is a censored variable. Stat Methods Med Res 27:3010-3025
Chambers, Mark S; Rugo, Hope S; Litton, Jennifer K et al. (2018) Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc 149:291-298
Echeverria, Gloria V; Powell, Emily; Seth, Sahil et al. (2018) High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun 9:5079
Smith, Brian; Hsu, Yi-Hsin; Flores, Rene et al. (2018) Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. Am J Cancer Res 8:183-191
Kuerer, Henry M; Rauch, Gaiane M; Krishnamurthy, Savitri et al. (2018) A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg 267:946-951

Showing the most recent 10 out of 12418 publications